UK – Mesenbio, a University of York (UK) spin-out that is developing a novel treatment for arthritis created from engineered human stem cells, raised £1.4m in funding.
The round was co-led by DSW Ventures and NG Bio alongside grant funding from Innovate UK. The funding will enable the company to create three new roles, develop pilot manufacturing processes, carry out pre-clinical studies and prepare the regulatory dossier in readiness for clinical trials.Founded by Professor Paul Genever and Dr David Kuntin and based on their work at the University of York’s Biomedical Research Institute, Mesenbio is advancing a novel treatment for arthritis created from engineered human stem cells. The treatment will initially target rheumatoid arthritis, an autoimmune disease that impacts nearly half a million adults and children in the UK alone, causing debilitating joint pain and inflammation of the hands, knees, elbows, ankles, and wrists.The treatment is based on nano-sized messengers created from engineered human stem cells that not only curb inflammation but can kick-start the process of regenerating damaged tissue.09/01/2024
